Skip to main content

Miraculins to Validate Colorectal Biomarkers with Fox Chase Cancer Center

NEW YORK, June 13 (GenomeWeb News) - Miraculins, a cancer biomarker discovery firm, said today that it will collaborate with FoxChaseCancerCenter to validate markers in a colorectal cancer diagnostic project.


Miraculins picked up the biomarkers in its acquisition of Europroteome's IP portfolio last June.


Under the terms of the agreement, FoxChaseCancerCenter will provide a "significant number" of biological samples, which Miraculins will process with its BEST platform, which combines proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.


The company said that its test has sensitivity and specificity of more than 80 percent.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.